富卫香港:上半年新业务保单数目增34% 第三季增长动力持续
富卫香港及澳门首席产品总监余(柏)坚表示,富卫上半年新业务保单数目按年增加34%,较2019年疫情前增长61%。受惠新产品带动内地客销售,预期第三季增长动力持续强劲。
他提到,富卫香港去年的理赔统计显示,2022年身故和危疾赔偿金额较2019年疫情前分别提升113%和40%,癌症则继续成为身故和危疾赔偿的第一大成因。
该报告亦显示,去年危疾赔偿个案中超过一半的被保人为39岁或以下,反映危疾年轻化。有见及此,富卫推出「危疾致尚保」系列,提供涵盖家庭三代,并为夹世代应对未来可能发生之长者疾病的危疾保障及支援服务。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.